Valuation: UCB

Market Cap 5.2TCr 5.81TCr 4.81TCr 4.36TCr 8.15TCr 5,53200Cr 8.29TCr 58TCr 23TCr 2,89300Cr 22TCr 21TCr 9,16100Cr P/E 2026 *
24.6x
P/E 2027 * 21x
Enterprise Value 5.22TCr 5.83TCr 4.83TCr 4.37TCr 8.18TCr 5,54900Cr 8.31TCr 58TCr 23TCr 2,90200Cr 22TCr 21TCr 9,19000Cr EV / Sales 2026 *
5.86x
EV / Sales 2027 * 5.04x
Free-Float
61.59%
Yield 2026 *
0.53%
Yield 2027 * 0.55%
1 day-0.88%
1 week+32.11%
Current month+31.79%
1 month+26.07%
3 months+9.88%
6 months+13.10%
Current year+13.29%
1 week 205.8
Extreme 205.8
276.5
1 month 197.45
Extreme 197.45
276.5
Current year 197.45
Extreme 197.45
289.5
1 year 197.45
Extreme 197.45
289.5
3 years 65.4
Extreme 65.4
289.5
5 years 65.4
Extreme 65.4
289.5
10 years 54.84
Extreme 54.84
289.5
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
15/01/26 Exercice

Executive/Senior Manager

3,000 0.0015%
15/01/26 Exercice

Executive/Senior Manager

3,000 0.0015%
15/01/26 Buy

Director

500 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%+32.11%+11.14%+275.00% 5.82TCr
+0.45%+3.13%+54.78%+125.16% 1,13500Cr
+0.94%+4.93%+39.94%+78.72% 64TCr
+0.39%+1.44%+25.75%+97.48% 50TCr
+1.43%+4.56%+46.20%+66.91% 38TCr
-3.21%-2.10%+59.78%+33.22% 36TCr
-0.41%+2.23%+22.48%+48.54% 29TCr
+0.23%+3.28%+2.57%+21.89% 27TCr
+1.22%+4.63%+52.71%+64.85% 24TCr
+1.70%+3.67%+31.73%+102.15% 19TCr
Average +0.16%+4.77%+34.71%+91.39% 40.62TCr
Weighted average by Cap. +0.27%+2.08%+40.89%+86.12%

Financials

2026 *2027 *
Net sales 890.64Cr 996.02Cr 824Cr 746.07Cr 1.4TCr 95TCr 1.42TCr 9.92TCr 3.92TCr 50TCr 3.74TCr 3.66TCr 1,56900Cr 990.92Cr 1.11TCr 916.77Cr 830.07Cr 1.55TCr 1,05400Cr 1.58TCr 11TCr 4.36TCr 55TCr 4.16TCr 4.07TCr 1,74600Cr
Net income 218.46Cr 244.31Cr 202.11Cr 183Cr 342.5Cr 23TCr 348.11Cr 2.43TCr 962.06Cr 12TCr 916.93Cr 897.34Cr 38TCr 252.65Cr 282.54Cr 233.74Cr 211.64Cr 396.1Cr 27TCr 402.59Cr 2.81TCr 1.11TCr 14TCr 1.06TCr 1.04TCr 45TCr
Net Debt 16Cr 18Cr 15Cr 14Cr 25Cr 1.72TCr 26Cr 179.94Cr 71Cr 899.46Cr 68Cr 66Cr 2.85TCr -201.5Cr -225.34Cr -186.42Cr -168.79Cr -315.91Cr -21TCr -321.09Cr -2.24TCr -887.38Cr -11TCr -845.75Cr -827.68Cr -36TCr
Projected Income Statement - Annual - UCB
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
26/26/26 €270.30 -0.88% 4,03,103
23/26/23 €272.70 +5.25% 5,70,629
22/26/22 €259.10 +21.64% 9,95,103
21/26/21 €213.00 -2.74% 2,30,878
20/26/20 €219.00 +6.73% 4,19,213
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
272.70EUR
Average target price
291.58EUR
Spread / Average Target
+6.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - UCB